
Anushua Sinha, MD, discussed the findings, highlighting a 60.4% reduction in medically attended lower respiratory infections and significant decreases in RSV-related hospitalizations.
Infectious Disease Physician, Senior Scientist, and Product Development Team Lead at Merck.
Anushua Sinha, MD, discussed the findings, highlighting a 60.4% reduction in medically attended lower respiratory infections and significant decreases in RSV-related hospitalizations.
Published: October 22nd 2024 | Updated: